Diabetes and Cardiometabolic Disease
We will cover the prevalence, diagnosis, treatment, and management of obesity, along with related cardiometabolic disorders.
Diabetes and Cardiometabolic Disease Read More »
Diabetes
Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial
We aimed to assess the effects of empagliflozin and linagliptin in mono- and combination therapy compared to the initiation and intensification of SU-derivative gliclazide treatment on fasting and postprandial kidney haemodynamic function.
Continuous Glucose Monitoring Metrics Predict All-Cause Mortality in Diabetes: A Real-world Long-term Study
Investigate the association between continuous glucose monitoring (CGM)-derived glucose metrics and all-cause mortality in patients with type 1 or type 2 diabetes (T1D or T2D).
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
Oral semaglutide may be an effective treatment for overweight or obesity and associated complications in East Asian individuals.
Dr. Scott Issacs Case Study
Welcome to our case study video featuring Prof. Scott Issacs, where we delve into the management of a complex case involving a 56-year-old patient with a seven-year history of type 2 diabetes, initially preceded by prediabetes.
Dr. Scott Issacs Case Study Read More »
Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta-analysis with focus on an Asian subpopulation
This updated meta-analysis investigates the efficacy and safety of combining sodium-glucose cotransporter 2 inhibitors (SGLT2is) with dipeptidyl peptidase-4 inhibitors (DPP4is) in treating type 2 diabetes (T2D), especially in Asian subpopulations.
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide–semaglutide (2.4 mg each) or placebo, along with lifestyle intervention, for 68 weeks.
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes Read More »
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
In this phase 3, double-blind, placebo-controlled trial, we randomly assigned participants in a 1:1:1:1 ratio to receive orforglipron at one of three doses (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Read More »
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Herein, we assess current remission paradigms, emphasising the discordance among definitions and the need for approaches that better align with clinical realities and patient needs.
Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes
Finally, the review summarizes recent clinical trial findings on strategies that enhance the adoption of SGLT2i and other cardioprotective agents through a multifaceted approach, aiming to improve real-world adoption for patients with T2D and/or cardiovascular and kidney diseases.